Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment
Histologically or cytologically confirmed advanced, metastatic, or recurrent colorectal cancer, supported by radiological findings.
Age 18-75 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Disease progression or failure of at least second-line standard therapy.
Voluntary provision of written informed consent.
You may not be if
Prior treatment with a JAK1 inhibitor.
Active autoimmune disease or primary immunodeficiency within the previous 2 years.
Known allergy to monoclonal antibodies, sodium carboxymethylcellulose, or any of their components.
Major cardiovascular or cerebrovascular diseases, including stroke or myocardial infarction within 6 months before enrollment, uncontrolled hypertension, unstable angina, heart failure (New York Heart Association \[NYHA\] class II-IV), or severe arrhythmias requiring pharmacological treatment.
History of other malignancies within 5 years before enrollment, except for excised basal cell carcinoma of the skin or cervical carcinoma in situ.
Membership in vulnerable populations, including individuals with mental or cognitive impairment, critically ill patients, minors, pregnant or breastfeeding women.
Severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, or other conditions that severely impair pulmonary function.
Severe hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 × the upper limit of normal (ULN) in patients without liver metastases, or ≥ 5 × ULN in patients with liver metastases.
Severe renal impairment, defined as creatinine clearance (CrCl) \< 30 mL/min.
Toxicities from previous anticancer treatment that have not recovered to Grade 1 or lower, except for alopecia.
History of venous thrombosis.
Active tuberculosis or active bacterial, fungal, or viral infection.
